Neuroendocrine Prostate Cancer Market Showing Steady Growth Toward 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Neuroendocrine Prostate Cancer Market By 2030 Starting From Its 2026 Size?

The neuroendocrine prostate cancer market size has experienced significant expansion over recent years. It is projected to increase from $1.05 billion in 2025 to $1.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.5%. The historical growth in this market can be attributed to a rise in prostate cancer diagnoses, the emergence of long-term hormone therapy resistance, the expansion of oncology drug pipelines, advancements in molecular pathology testing, and heightened cancer center specialization.

The neuroendocrine prostate cancer market is projected to experience substantial growth over the next few years. It is set to reach $1.6 billion in 2030, achieving a compound annual growth rate (CAGR) of 8.7%. This expansion during the forecast period can be attributed to the increasing adoption of precision oncology, the rise of biomarker-based treatments, the broadening of targeted therapies, enhanced funding for rare cancer research, and wider utilization of genomic testing. Prominent trends expected in this period include biomarker-driven patient stratification, the implementation of combination oncology therapy protocols, advanced molecular diagnostic testing, the expansion of rare cancer clinical trials, and innovative targeted radiopharmaceutical approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33242&type=smp

Which Market Drivers Are Supporting The Expansion Of The Neuroendocrine Prostate Cancer Market?

The expanding occurrence of prostate cancer is anticipated to drive the neuroendocrine prostate cancer market’s expansion in the future. This condition is defined as a malignant tumor that develops in the prostate gland, primarily affecting men over the age of 50. Its increasing frequency is primarily attributed to the growing aging male population, given that advancing age constitutes a significant risk factor for developing the illness. The widespread presence of prostate cancer contributes to the growth of neuroendocrine prostate cancer through several mechanisms: enlarging the overall patient pool, increasing long-term exposure to androgen-deprivation therapies, and consequently elevating the probability of developing treatment-induced neuroendocrine differentiation in advanced and castration-resistant disease stages. As an illustration, in January 2025, the Centers for Disease Control and Prevention (CDC), a U.S. federal public health agency, disclosed that during 2023, 255,395 new cases of prostate cancer were diagnosed in the United States, and 33,881 men died from the disease. Consequently, the rising incidence of prostate cancer is a key factor propelling the expansion of the neuroendocrine prostate cancer market.

Which Segment Categories Define The Neuroendocrine Prostate Cancer Market?

The neuroendocrine prostate cancer market covered in this report is segmented –

1) By Treatment: Chemotherapy; Hormonal Therapy

2) By Therapeutics: Immunotherapy; Targeted Therapy

3) By Disease Stage: Localized Disease; Advanced Disease; Metastatic Disease

4) By End Users: Hospitals; Oncology Specialty Clinics; Cancer Research Institutes

Subsegments:

1) By Chemotherapy: Platinum Based Chemotherapy; Taxane Based Chemotherapy; Combination Chemotherapy; Second Line Chemotherapy

2) By Hormonal Therapy: Androgen Deprivation Therapy; Androgen Receptor Inhibition; Hormone Synthesis Inhibition; Combined Hormonal Therapy

What Major Market Trends Are Driving Changes In The Neuroendocrine Prostate Cancer Market?

Leading companies in the neuroendocrine prostate cancer market are concentrating on developing innovative medications, such as immune-modulating small-molecule therapies, to improve immune response and enhance patient outcomes. Immune-modulating small-molecule therapies are orally administered compounds that stimulate the body’s innate immune system to identify and attack cancer cells, thereby helping to overcome resistance to traditional treatments like hormone therapy or chemotherapy by boosting the anti-tumor immune response. For example, in February 2024, BioXcel Therapeutics, a US-based clinical-stage biopharmaceutical company, received Fast Track Designation from the U.S. Food and Drug Administration for BXCL701, an immune-modulating small-molecule therapy for neuroendocrine prostate cancer. BXCL701 is designed to activate the NLRP3 inflammasome, increase cytokine release, and prepare the immune system to target tumor cells, offering a novel strategy that complements immune checkpoint inhibitors. The Fast Track Designation is anticipated to accelerate the clinical development and regulatory review of BXCL701, highlighting its potential to address significant unmet medical needs in aggressive and treatment-resistant prostate cancer.

Which Major Players Dominate The Neuroendocrine Prostate Cancer Market?

Major companies operating in the neuroendocrine prostate cancer market are Novartis AG, Amgen Inc., Phanes Therapeutics Inc., and BioXcel Therapeutics Inc.

Read the full neuroendocrine prostate cancer market report here:

https://www.thebusinessresearchcompany.com/report/neuroendocrine-prostate-cancer-market-report

Which Region Currently Holds The Largest Share Of The Neuroendocrine Prostate Cancer Market?

North America was the largest region in the neuroendocrine prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neuroendocrine Prostate Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33242&type=smp

Browse Through More Reports Similar to the Global Neuroendocrine Prostate Cancer Market 2026, By The Business Research Company

Neuroendocrine Tumor Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuroendocrine-tumor-treatment-global-market-report

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795